Want to see TSE:CL full AI Analyst Report?
CL Stock Chart & Stats
C$0.96
-C$0.03(-3.13%)
At close: 4:00 PM EDT
C$0.96
-C$0.03(-3.13%)
Day’s Range― - ―
52-Week RangeC$0.89 - C$3.12
Previous CloseN/A
Volume26.25K
Average Volume (3M)75.25K
Market Cap
C$502.31M
Enterprise ValueC$1.17K
Total Cash (Recent Filing)C$32.87M
Total Debt (Recent Filing)C$592.02M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Nov 05, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding355,588,680
10 Day Avg. Volume78,707
30 Day Avg. Volume75,253
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.22
Price to Sales (P/S)0.62
P/FCF Ratio10.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$2.53Price Target Upside163.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.03
Revenue Forecast (FY)C$668.30M
Bulls Say, Bears Say
Bulls Say
Vertical Integration And Multi-state FootprintOwning cultivation, manufacturing and retail across multiple states creates durable control of supply, margin capture and brand placement. This vertical model reduces reliance on third-party suppliers, supports margin preservation amid pricing pressure, and enables scale in regulated state markets.
High And Improving Gross And EBITDA MarginsSustained high gross margins (~48% TTM, 51% Q1) and mid-20s EBITDA margins signal structural cost and yield improvements in cultivation and manufacturing. These margin profiles provide a durable buffer against industry price compression and support reinvestment, debt servicing and margin recovery over the medium term.
Strong Retail Unit Economics And Disciplined Store GrowthOutperforming Sunnyside retail economics (>30% revenue per store) plus accretive expansion (11 stores YTD, PA footprint to 27) offer durable revenue density and better ROI on new openings. Strong unit economics support selective rollout and M&A that can sustainably lift company-level revenue and margins.
Bears Say
Elevated Leverage And Negative ROEA debt-to-equity ratio near 1.65 with materially negative ROE indicates capital is not generating sufficient returns. Elevated leverage reduces financial flexibility for capex or deals, increases refinancing and interest risk, and constrains ability to absorb market shocks across the next several quarters.
Volatile And Modest Free Cash Flow GenerationUneven FCF — modest TTM after swings year-to-year — limits self-funding for expansion and debt reduction. With operating cash covering only a portion of losses and seasonal cash use, the company may remain reliant on external capital or need to curtail growth if volatility persists over the medium term.
Regulatory And Market Uncertainty (rescheduling, Excise Changes)Unresolved rescheduling/280E implementation and recent market exits/tax changes create structural planning uncertainty. Potential tax relief timing and scope are unknown, while state-level exits and excise taxes can permanently alter revenue base and margins, complicating medium-term forecasting and capital allocation.
Cresco Labs News
CL FAQ
What was Cresco Labs OTC’s price range in the past 12 months?
Cresco Labs OTC lowest stock price was C$0.89 and its highest was C$3.12 in the past 12 months.
What is Cresco Labs OTC’s market cap?
Cresco Labs OTC’s market cap is C$502.31M.
When is Cresco Labs OTC’s upcoming earnings report date?
Cresco Labs OTC’s upcoming earnings report date is Nov 05, 2026 which is in 82 days.
How were Cresco Labs OTC’s earnings last quarter?
Cresco Labs OTC released its earnings results on Aug 06, 2026. The company reported C$0.056 earnings per share for the quarter, beating the consensus estimate of -C$0.022 by C$0.078.
Is Cresco Labs OTC overvalued?
According to Wall Street analysts Cresco Labs OTC’s price is currently Undervalued.
Does Cresco Labs OTC pay dividends?
Cresco Labs OTC does not currently pay dividends.
What is Cresco Labs OTC’s EPS estimate?
Cresco Labs OTC’s EPS estimate is -0.02.
How many shares outstanding does Cresco Labs OTC have?
Cresco Labs OTC has 355,588,680 shares outstanding.
What happened to Cresco Labs OTC’s price movement after its last earnings report?
Cresco Labs OTC reported an EPS of C$0.056 in its last earnings report, beating expectations of -C$0.022. Following the earnings report the stock price went up 13.333%.
Which hedge fund is a major shareholder of Cresco Labs OTC?
Currently, no hedge funds are holding shares in TSE:CL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cresco Labs Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$2.53 (163.56% Upside)
C$2.53 (163.56% Upside)
Blogger Sentiment
Bullish
TSE:CL Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth C$84.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.2%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.27%
Trailing 12-Months
Company Description
Cresco Labs OTC
Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.
CL Company Deck
CL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic outlook: management delivered solid Q1 margins and EBITDA from a streamlined cost structure, achieved meaningful operational and licensing wins (PA store expansion, Ohio openings, Kentucky harvest, Texas license) and provided constructive Q2 growth guidance (~+10% revenue). Offsets include near-term revenue headwinds from the planned California exit and Michigan excise tax, ongoing pricing compression, seasonal cash flow timing, and unresolved regulatory details around rescheduling (including the scope and timing of 280E relief). On balance, operational momentum, accretive M&A activity, and licensing progress outweigh the short-term market and regulatory challenges.View all TSE:CL earnings summariesCL Stock 12 Month Forecast
Average Price Target
C$2.53
▲(163.56% Upside)